Zomedica Corp. (NYSEAMERICAN:ZOM - Get Free Report)'s stock price was down 2.2% during mid-day trading on Thursday . The company traded as low as $0.13 and last traded at $0.14. Approximately 8,794,663 shares traded hands during mid-day trading, a decline of 48% from the average daily volume of 16,965,762 shares. The stock had previously closed at $0.14.
Analyst Upgrades and Downgrades
Separately, Noble Financial upgraded Zomedica to a "strong-buy" rating in a report on Monday, November 11th.
Get Our Latest Research Report on ZOM
Zomedica Stock Down 5.2 %
The company has a market capitalization of $128.37 million, a P/E ratio of -2.18 and a beta of 1.04.
Hedge Funds Weigh In On Zomedica
An institutional investor recently bought a new position in Zomedica stock. Jane Street Group LLC acquired a new position in shares of Zomedica Corp. (NYSEAMERICAN:ZOM - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 179,074 shares of the company's stock, valued at approximately $25,000. 8.95% of the stock is currently owned by hedge funds and other institutional investors.
About Zomedica
(
Get Free Report)
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system.
See Also
Before you consider Zomedica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zomedica wasn't on the list.
While Zomedica currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for January 2025. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
